Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 639-646, December 2008

Are new agents really making a difference in MDS?

  • Richard M. Stone, MD (Associate Professor of Medicine, Harvard Medical School Director, Adult Leukemia Program)

      Affiliations

    • Corresponding Author InformationAdult Leukemia Program, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Tel.: +1 617 632 2214; Fax: +1 617 632 2933.

Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-6926(08)00055-8

doi:10.1016/j.beha.2008.06.004

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 639-646, December 2008

Article Tools